Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients

Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients

Abstract Background Malaria remains one of the most important infectious diseases. Treatment options for severe malaria are limited and the choline analogue SAR97276A is a novel chemical entity that was developed primarily as treatment for severe malaria. Before starting clinical investigations in s...

Full description

Bibliographic Details
Main Authors: Jana Held, Christian Supan, Carmen L. Ospina Salazar, Halidou Tinto, Léa Nadège Bonkian, Alain Nahum, Ali Sié, Salim Abdulla, Cathy Cantalloube, Elhadj Djeriou, Marielle Bouyou-Akotet, Bernhards Ogutu, Benjamin Mordmüller, Andrea Kreidenweiss, Mohamadou Siribie, Sodiomon B. Sirima, Peter G. Kremsner
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Malaria Journal
Subjects:
Malaria
P. falciparum
SAR97276A
Choline analogue
Phase 2
Africa
Online Access:http://link.springer.com/article/10.1186/s12936-017-1832-x

Internet

http://link.springer.com/article/10.1186/s12936-017-1832-x

Similar Items